article thumbnail

NHC Comments on Negotiation Data Elements and Drug Price Negotiation Process for Initial Price Applicability Year 2027 under Sections 11001 and 11002 of the IRA ICR Forms

Putting Patients First Blog

Overall, while the NHC appreciates CMS’ intent to streamline the data submission process and make it more accessible, we encourage ongoing dialogue and adjustments to ensure that the process remains patient-centered, efficient, and capable of capturing the full spectrum of information necessary to inform meaningful drug price negotiations.

article thumbnail

NHC Comments on Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027

Putting Patients First Blog

General Comments The NHC appreciates CMS’ commitment to actively engaging with stakeholders, including patients, consumer advocates, and health experts, in implementing the Medicare Drug Price Negotiation Program (DPNP). Prior authorization and association with delayed or discontinued prescription fills. and Keating, N.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Three strategies for managing loss of exclusivity successfully

pharmaphorum

Drug prices to plummet in wave of expiring patents”. Price decay after loss of brand exclusivity”. These are just three headlines that come up when you Google “drug patent expiry”. Between December 1, 2018 and January 31, 2019, 65% of erectile dysfunction prescriptions filled were for Viagra or its generic version 12.

article thumbnail

ProxsysRx’s MedServRx: The Prescription-Drug Advantage For Patients And Their Providers

Proxsys Rx

The cost of prescription non-adherence to the community at large — which ultimately pays for uncompensated care (particularly for hospital readmissions) — is staggering. It’s an absolutely sound business model for a tremendous amount of prescriptions, at least where out-of-pocket costs to patients is concerned.

article thumbnail

The Lilly Digest

Ramblings of a pharmacist

I’ll also note that I’m not certain that the “Pharmacy” revenue is ONLY prescription fills. Digest per prescription revenue figure is believable (it’s also down about $6 since I started paying attention to the Digest , hence my annoyance at people that blame pharmacists for “skyrocketing drug prices.”